Heart failure & cardiomyopathies
Diffuse myocardial fibrosis precedes subclinical functional myocardial impairment and provides prognostic information in systemic sclerosis
Authors' conclusion
Subclinical myocardial involvement first manifests as diffuse myocardial fibrosis identified by the expansion of ECV and increased native T1 in VEDOSS patients while subtle functional impairment only occurs in established SSc. Native T1 and GLS have prognostic value for all-cause mortality in SSc patients.
Study context
- Population
- Patients with systemic sclerosis (very early diagnosis of SSc (VEDOSS) and established systemic sclerosis (SSc)) and healthy controls undergoing cardiovascular magnetic resonance (CMR)110 SSc patients
- Participants
- 24 / 86 / 15
- Exposure
- VEDOSS and established SSc vs healthy controls
- VEDOSSn = 24
- Established SScn = 86
- Controlsn = 15reference
- Outcome
- CMR diffuse myocardial fibrosis (native T1, ECV) and myocardial strain (GLS, GCS); association with mortality
- Follow-up
- Median 7.0 years (IQR 6.0-7.3 years)
Main finding
As reported in the abstract
- Native T1 and extracellular volume (ECV) elevated in VEDOSS and SSc vs controls
- P < 0.001
- GLS similar in VEDOSS and controls, significantly impaired in established SSc
- P < 0.001
- GCS similar over all groups
- P = 0.88
Observational data: associations, not effects.
Further findings
All-cause mortality (12 deaths) · median 7.0 years
| HR (95% CI) | P value | ||
|---|---|---|---|
| Elevated native T1 | 5.8 (1.7–20.4) | P = 0.006 | |
| Reduced GLS | 6.1 (1.3–29.9) | P = 0.038 | |
| 0.050.21520Hazard ratio (log scale) |
CV mortality
- Only native T1 predictive
- P < 0.001
Original publication
Diffuse myocardial fibrosis precedes subclinical functional myocardial impairment and provides prognostic information in systemic sclerosis. Eur Heart J Cardiovasc Imaging. Published 26 May 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →